FORT WASHINGTON, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, […]

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European […]

BRIDGEWATER, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader […]

THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) (“LGI Homes” or the “Company”) today […]

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, […]

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat […]

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are […]

ATHENS, Greece, Nov. 12, 2024 (GLOBE NEWSWIRE) — TEN Ltd. (“TEN”) (NYSE: TEN) (the “Company”), a leading diversified crude, product […]